ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Fisetin: a multitarget flavonol bridging oxidative stress, inflammation, aging, and cancer.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synergistic Induction of Caspase-8-Mediated Leukaemic Cell Death by Fisetin and Pinocembrin.International journal of molecular sciences · 2026Article
- Exploring the Senotherapeutic Potential of Polyphenols in Aging and Disease: A Literature Review.International journal of molecular sciences · 2026Review
- Impact of Oxidative Stress-Driven Ferroptosis in Neurodegeneration.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fisetin is a naturally occurring dietary flavonoid that is abundant in fruits and vegetables such as strawberries, apples, and onions. It has gained significant scholarly attention owing to its broad pharmacological prospects. This compound exhibits robust antioxidant and anti-inflammatory activities and has notable anticancer and neuroprotective effects. Fisetin strongly modulates key cellular signaling pathways, induces apoptosis, and inhibits tumor growth, thus protecting cells against oxidative damage and neurodegenerative events. Additional hepatoprotective, antiviral, and gastroprotective actions further highlight the therapeutic importance of this compound. This review presents an integrated and detailed analysis of the pharmacokinetics, diverse biological activities, and molecular mechanisms of action of fisetin underlying its therapeutic actions. It also assesses its toxicological profile, including safety considerations such as genotoxicity at relatively high concentrations. Poor solubility and low bioavailability are key limitations, along with emerging formulation methods designed to facilitate its clinical utility. Furthermore, this review synthesizes evidence from ongoing trials and outlines future priorities. Collectively, these findings position fisetin as a promising therapeutic candidate with potential across a wide range of disease conditions.
Indexed as
Identifiers
41538057What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.